Scholar Rock Holding Corp. (SRRK)

Scholar Rock's stock fell by over 13% after the FDA designated Catalent Indiana as "Official Action Indicated" (OAI) in October 2025. In December 2025, the company reported $60.4 million from the exercise of outstanding warrants. In March 2026, Scholar Rock reported its Fourth Quarter and Full Year 2025 financial results, including a net loss of $91.0 million for Q4 2025 and $377.9 million for the full year, with no revenue recorded for either period. The company announced securing a new debt facility for up to $550 million with Blue Owl Capital to support apitegromab commercialization in March 2026, and reaffirmed its guidance to resubmit the apitegromab BLA and launch in the U.S. in 2026, leading to a surge in shares. Scholar Rock officially resubmitted its Biologics License Application (BLA) to the FDA for apitegromab for the treatment of children and adults with SMA on March 31, 2026, causing the stock to surge and hit new 52-week highs in early April 2026. Analyst price targets for SRRK were increased in April 2026, and the stock continued to perform strongly, with a 13.4% increase since January 1, 2026, and a 44.2% increase over the past six months.

There is no specific information available indicating demand seasonality for Scholar Rock Holding Corp.'s products and services. The demand for its specialized products is primarily driven by disease prevalence, regulatory approvals, and clinical need rather than typical seasonal fluctuations.

Scholar Rock Holding Corp. is a biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases where protein growth factor signaling plays a fundamental role, operating within the Healthcare sector and Biotechnology industry. The company's core business revolves around its proprietary platform, which leverages a novel understanding of transforming growth factor beta (TGFβ) superfamily biology to develop monoclonal antibodies that selectively target the precursor, or latent, forms of growth factors. Apitegromab is an investigational muscle-targeted therapy for the treatment of Spinal Muscular Atrophy (SMA) in children and adults and is also being developed for facioscapulohumeral muscular dystrophy (FSHD). SRK-439 is an investigational subcutaneously administered anti-pro/latent myostatin antibody being developed for rare neuromuscular diseases and cardiometabolic disorders, including obesity. SRK-181 is an investigational inhibitor of the activation of latent TGFβ1 being developed for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies. SRK-373 is a preclinical selective inhibitor of the latent TGFβ1 isoform for fibrotic diseases. SRK-256 is a preclinical inhibitor of RGMc (hemojuvelin) for iron-restricted anemias.

Scholar Rock Holding Corp. is headquartered in Cambridge, Massachusetts, United States. The company plans to commercially launch apitegromab in Europe, starting with Germany, anticipated in the second half of 2026, and intends to expand globally to serve the SMA community worldwide.

Scholar Rock's brand reputation has been influenced by regulatory progress and clinical trial updates for apitegromab. The initial rejection of the BLA for apitegromab and the "Official Action Indicated" (OAI) designation for its third-party manufacturing facility posed a challenge to its reputation. Subsequent positive developments, such as the constructive meeting with the FDA and the successful resubmission of the BLA for apitegromab, have likely bolstered its reputation. Analyst ratings reflect a positive sentiment, with a consensus "Buy" rating, and the company's focus on addressing high unmet medical needs in rare diseases contributes positively to its reputation.

Scholar Rock Holding Corp. has significant institutional ownership, with 286 institutional owners holding a total of 123,167,871 shares. Major institutional shareholders include Fmr Llc, Siren, L.L.C., BlackRock, Inc., Samsara BioCapital, LLC, Price T Rowe Associates Inc /md/, Wellington Management Group Llp, Redmile Group, LLC, Vanguard Group Inc, Bellevue Group AG, and State Street Corp. Institutional shareholders collectively own 107.52% of the company's stock, while insiders own 71.13%. Srinivas Akkaraju is the largest individual shareholder, owning 16.82 million shares, representing 14.64% of the company.